CA_logo-blueCaring Ambassadors

Hepatitis C Program Newsletter

www.HepCChallenge.org

February, 2010

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Snow KK, Bonkovsky HL, Fontana RJ, et al. Aliment Pharmacol Ther. 2010 Jan 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20070284?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Efficacy and tolerability of pegylated interferon-a(2a) plus ribavirin versus pegylated interferon-a(2b) plus ribavirin in treatment-naive chronic hepatitis c patients. Lee S, Kim IH, Kim SH, et al. Intervirology. 2010 Jan 13;53(3):146-153. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20068348?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=36

 

Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Fontana RJ, Bieliauskas LA, Back-Madruga C, et al. Am J Gastroenterol. 2010 Jan 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20104219?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to hepatitis C treatment. Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC. Int J Med Sci. 2010 Jan 22;7(1):36-42.

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Suwantarat%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract

 

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis c. Huang CF, Yang JF, Dai CY, et al. J Infect Dis. 2010 Jan 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20102281?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Propensity score matching in the evaluation of drug therapy management programs: an illustrative analysis of a program for patients with hepatitis C virus. Hussein M, Benner JS, Lee D, et al. Qual Manag Health Care. 2010 Jan-Mar;19(1):25-33.

http://www.ncbi.nlm.nih.gov/pubmed/20042931?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. Falasca K, Ucciferri C, Mancino P, et al. J Med Virol. 2010 Jan;82(1):49-56.

http://www.ncbi.nlm.nih.gov/pubmed/19950239?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Program characteristics associated with testing for HIV and hepatitis C in Veterans substance use disorder clinics. McInnes DK, Hyun JK, Trafton JA, Asch SM, Gifford AL. Psychiatr Serv. 2010 Jan;61(1):90-4.

http://www.ncbi.nlm.nih.gov/pubmed/20044426?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

 

Financial incentives and accountability for integrated medical care in Department of Veterans Affairs mental health programs. Kilbourne AM, Greenwald DE, Hermann RC,et al. Psychiatr Serv. 2010 Jan;61(1):38-44.

http://www.ncbi.nlm.nih.gov/pubmed/20044416?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

 

Peg-inf alpha/rbv combination therapy for chronic hepatitis c patients increases serum ferritin level while it improves sustained viral response rate. Yada N, Kudo M, Chung H,et al. Intervirology. 2010;53(1):60-5. Epub 2010 Jan 5.

http://www.ncbi.nlm.nih.gov/pubmed/20068343?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

 

Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks. Ueda T, Chung H, Kudo M, et al. Intervirology. 2010;53(1):55-9. Epub 2010 Jan 5.

http://www.ncbi.nlm.nih.gov/pubmed/20068342?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=6

 

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. Nakagawa M, Sakamoto N, Ueyama M, et al. J Gastroenterol. 2010 Jan 30. [Epub ahead of

http://www.ncbi.nlm.nih.gov/pubmed/20112032?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b. Toyoda H, Kumada T, Kiriyama S, et al. J Clin Virol. 2010 Jan 27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20116330?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

 

 

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. Castellanos M, Cinza Z, Dorta Z, et al. J Gene Med. 2010 Jan;12(1):107-16.

http://www.ncbi.nlm.nih.gov/pubmed/19866482?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=3

 

Basic and Applied Science, Pre-Clinical Studies

 

Pathogenesis of hepatitis C virus infection in Tupaia belangeri. Amako Y, Tsukiyama-Kohara K, Katsume A, et al. Virol. 2010 Jan;84(1):303-11.

http://www.ncbi.nlm.nih.gov/pubmed/19846521?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

 

ER targeting and retention of the HCV NS4B protein relies on the concerted action of multiple structural features including its transmembrane domains. Boleti H, Smirlis D, Dalagiorgou G, et al. Mol Membr Biol. 2010 Jan;27(1):50-74.

http://www.ncbi.nlm.nih.gov/pubmed/20001747?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. Diamond DL, Syder AJ, Jacobs et al. PLoS Pathog. 2010 Jan;6(1):e1000719. Epub 2010 Jan 8.

http://www.ncbi.nlm.nih.gov/pubmed/20062526?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. Kobayashi M, Akuta N, Suzuki F, et al. J Med Virol. 2010 Jan;82(1):41-8.

http://www.ncbi.nlm.nih.gov/pubmed/19950230?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=6

 

Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. Vidal-Castiñeira JR, López-Vázquez A, Díaz-Peña R, et al. J Virol. 2010 Jan;84(1):475-81.

http://www.ncbi.nlm.nih.gov/pubmed/19846535?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Identification of hepatitis C virus NS5A inhibitors. Lemm JA, O'Boyle D 2nd, Liu M, et al. J Virol. 2010 Jan;84(1):482-91.

http://www.ncbi.nlm.nih.gov/pubmed/19812153?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

 

 

Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 alpha-mediated glycolytic adaptation. Ripoli M, D'Aprile A, Quarato G, et al. J Virol. 2010 Jan;84(1):647-60.

http://www.ncbi.nlm.nih.gov/pubmed/19846525?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

 

HIV/HCV Coinfection

 

Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable. Fätkenheuer G, Hoffmann C, Slim J, et al. J Acquir Immune Defic Syndr. 2010 Jan 1;53(1):78-85.

http://www.ncbi.nlm.nih.gov/pubmed/19838130?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=5

 

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.

Iorio A, Marchesini E, Awad T, Gluud LL. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004888.

http://www.ncbi.nlm.nih.gov/pubmed/20091566?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. Milazzo L, Caramma I, Mazzali C, et al. J Antimicrob Chemother. 2010 Jan 30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20118492?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. Sherman KE, Rouster SD, Stanford S, et al. J Infect Dis. 2010 Jan 27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20105080?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Treatment of acute hepatitis C in HIV infection. Vogel M, Rockstroh JK. J Antimicrob Chemother. 2010 Jan;65(1):4-9.

http://www.ncbi.nlm.nih.gov/pubmed/19861339?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=7

 

Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients. Shores NJ, Maida I, Perez-Saleme L, Núñez M. J Int Assoc Physicians AIDS Care (Chic Ill). 2010 Jan-Feb;9(1):15-9.

http://www.ncbi.nlm.nih.gov/pubmed/20071593?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

 

 

Rate and predictors of success in the retreatment of chronic hepatitis c Virus in HIV/HCV-coinfected patients with prior nonresponse or relapse. Labarga P, Vispo E, Barreiro P, et al. J Acquir Immune Defic Syndr. 2010 Jan 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20101191?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

HIV/Hepatitis c virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.

Osinusi A, Rasimas JJ, Bishop R, et al. J Acquir Immune Defic Syndr. 2010 Jan 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20101190?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Complementary and Alternative Medicine

 

An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. Nakamura M, Saito H, Ikeda M, Hokari R, Kato N, Hibi T, Miura S. World J Gastroenterol. 2010 Jan 14;16(2):184-92.

http://www.ncbi.nlm.nih.gov/pubmed/20066737?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Changing trends in hepatitis C infection over the past 50 years in Japan. Chung H, Ueda T, Kudo M. Intervirology. 2010;53(1):39-43. Epub 2010 Jan 5.

http://www.ncbi.nlm.nih.gov/pubmed/20068339?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=6

 

Preventive healthcare for underserved women: results of a prison survey. Nijhawan AE, Salloway R, Nunn AS, Poshkus M, Clarke JG. J Womens Health (Larchmt). 2010 Jan;19(1):17-22.

http://www.ncbi.nlm.nih.gov/pubmed/20088654?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

 

Comparing survival between peritoneal dialysis and hemodialysis treatment in ESRD patients with chronic hepatitis C infection. Chou CY, Wang IK, Liu JH, Lin HH, Wang SM, Huang CC. Perit Dial Int. 2010 Jan-Feb;30(1):86-90.

http://www.ncbi.nlm.nih.gov/pubmed/20056985?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

 

Non-invasive evaluation of hepatic fibrosis for type c chronic hepatitis. Tatsumi C, Kudo M, Ueshima K, et al. Intervirology. 2010;53(1):76-81. Epub 2010 Jan 5.

http://www.ncbi.nlm.nih.gov/pubmed/20068346?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1